



Clinical trial results:

Effect of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind placebo-controlled international multicentre study.

Study assessinG the morbi-mortality beNefits of the If inhibitor ivabradine in patients with coronary arterY disease (SIGNIFY).

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

EudraCT number	2009-011360-10
Trial protocol	ES PT GB NL FI LV HU CZ SK IE BE FR LT DE AT SE IT GR EE SI
Global end of trial date	24 January 2014 24 January 2014

Results information

Result version number	v2 (current)
This version publication date	22 July 2016
First version publication date	31 July 2015

Version creation reason	<ul style="list-style-type: none">• Correction of full data set Data correction due to a system error in EudraCT – Results
-------------------------	--

Trial information

Trial identification

Sponsor protocol code	CL3-16257-083
-----------------------	---------------

Additional study identifiers

ISRCTN number	ISRCTN61576291
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Institut de Recherches Internationales Servier
Sponsor organisation address	50 rue Carnot, Suresnes Cedex, France, 92284
Public contact	Therapeutic Innovation Pole, Institut de Recherches Internationales Servier 50 rue Carnot 92284 Suresnes Cedex, +33 155724366, clinicaltrials@servier.com
Scientific contact	Therapeutic Innovation Pole, Institut de Recherches Internationales Servier 50 rue Carnot 92284 Suresnes Cedex, +33 155724366, clinicaltrials@servier.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 January 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	24 January 2014
Global end of trial reached?	Yes
Global end of trial date	24 January 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate the superiority of ivabradine over placebo in the reduction of CV mortality or non-fatal myocardial infarction.

Protection of trial subjects:

Reason to discontinue the study treatment: study drug not tolerated, no longer appropriate or considered as contra-indicated.

The measurement of drug concentrations in blood was planned in the case of suspected overdose.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 September 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Korea, Republic of: 446
Country: Number of subjects enrolled	Kazakhstan: 141
Country: Number of subjects enrolled	Latvia: 440
Country: Number of subjects enrolled	Lithuania: 302
Country: Number of subjects enrolled	Macedonia, the former Yugoslav Republic of: 224
Country: Number of subjects enrolled	Malaysia: 74
Country: Number of subjects enrolled	Mexico: 559
Country: Number of subjects enrolled	Netherlands: 555
Country: Number of subjects enrolled	Norway: 56
Country: Number of subjects enrolled	Philippines: 30
Country: Number of subjects enrolled	Poland: 1157

Country: Number of subjects enrolled	Portugal: 27
Country: Number of subjects enrolled	Romania: 892
Country: Number of subjects enrolled	Russian Federation: 2119
Country: Number of subjects enrolled	Serbia: 210
Country: Number of subjects enrolled	Singapore: 21
Country: Number of subjects enrolled	Slovenia: 68
Country: Number of subjects enrolled	South Africa: 374
Country: Number of subjects enrolled	Spain: 235
Country: Number of subjects enrolled	Sweden: 57
Country: Number of subjects enrolled	Switzerland: 50
Country: Number of subjects enrolled	Taiwan: 198
Country: Number of subjects enrolled	Thailand: 96
Country: Number of subjects enrolled	Turkey: 96
Country: Number of subjects enrolled	Ukraine: 1894
Country: Number of subjects enrolled	United Kingdom: 118
Country: Number of subjects enrolled	Uruguay: 29
Country: Number of subjects enrolled	Vietnam: 171
Country: Number of subjects enrolled	Argentina: 954
Country: Number of subjects enrolled	Armenia: 239
Country: Number of subjects enrolled	Australia: 116
Country: Number of subjects enrolled	Austria: 19
Country: Number of subjects enrolled	Belgium: 52
Country: Number of subjects enrolled	Brazil: 853
Country: Number of subjects enrolled	Bulgaria: 1121
Country: Number of subjects enrolled	Canada: 254
Country: Number of subjects enrolled	China: 975
Country: Number of subjects enrolled	Croatia: 197
Country: Number of subjects enrolled	Czech Republic: 539
Country: Number of subjects enrolled	Denmark: 76
Country: Number of subjects enrolled	Estonia: 387
Country: Number of subjects enrolled	Finland: 8
Country: Number of subjects enrolled	France: 99
Country: Number of subjects enrolled	Georgia: 102
Country: Number of subjects enrolled	Germany: 309
Country: Number of subjects enrolled	Greece: 77
Country: Number of subjects enrolled	Hungary: 981
Country: Number of subjects enrolled	Slovakia: 379
Country: Number of subjects enrolled	India: 295
Country: Number of subjects enrolled	Ireland: 47
Country: Number of subjects enrolled	Italy: 384
Worldwide total number of subjects	19102
EEA total number of subjects	8582

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	10205
From 65 to 84 years	8789
85 years and over	108

Subject disposition

Recruitment

Recruitment details:

A total of 1181 centres in 51 countries screened at least one patient and 1139 centres included at least one patient.

Pre-assignment

Screening details:

A total of 23 164 patients were screened, 21 862 were selected and 19 107 were included. The Randomised Set comprised 19 102 patients: 9550 patients in the ivabradine group and 9552 in the placebo group. Of the 19 102 patients in the Randomised Set, 17 724 completed the study: 8830 patients in the ivabradine group and 8894 in the placebo group.

Period 1

Period 1 title	Post-randomisation period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Ivabradine

Arm description:

Patients taking Ivabradine

Arm type	Study drug
Investigational medicinal product name	Ivabradine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily at 12-hours intervals, in the morning and in the evening during meals.

Arm title	Placebo
------------------	---------

Arm description:

Patients taking placebo

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

5 mg, 7.5 mg or 10 mg matching tablets to be taken orally twice daily at 12-hours intervals, in the morning and in the evening during meals.

Number of subjects in period 1	Ivabradine	Placebo
Started	9550	9552
Completed	8830	8894
Not completed	720	658
Adverse event, serious fatal	485	458
Physician decision	1	-
Consent withdrawn by subject	231	199
Lost to follow-up	3	1

Baseline characteristics

Reporting groups

Reporting group title	Ivabradine
Reporting group description: Patients taking Ivabradine	
Reporting group title	Placebo
Reporting group description: Patients taking placebo	

Reporting group values	Ivabradine	Placebo	Total
Number of subjects	9550	9552	19102
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	5109	5096	10205
From 65-84 years	4387	4402	8789
85 years and over	54	54	108
Age continuous Units: years			
arithmetic mean	65	65	
standard deviation	± 7.2	± 7.3	-
Gender categorical Units: Subjects			
Female	2601	2662	5263
Male	6949	6890	13839

Subject analysis sets

Subject analysis set title	Randomised set
Subject analysis set type	Intention-to-treat
Subject analysis set description: All included patients with a randomisation number allocated by the IRS.	
Subject analysis set title	Safety set
Subject analysis set type	Safety analysis
Subject analysis set description: All patients having received at least one dose of study drug.	
Subject analysis set title	Randomised set angina
Subject analysis set type	Intention-to-treat
Subject analysis set description: All symptomatic angina patients of the RS having a CCS class ≥ II at baseline (defined as CCS class ≥ II at selection and inclusion).	
Subject analysis set title	Safety set angina

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

All symptomatic angina patients of the SS having a CCS class \geq II at baseline (defined as CCS class \geq II at selection and inclusion).

Reporting group values	Randomised set	Safety set	Randomised set angina
Number of subjects	19102	19083	1204
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	5109		
From 65-84 years	4387		
85 years and over	54		
Age continuous Units: years			
arithmetic mean	65		
standard deviation	± 7.2	\pm	\pm
Gender categorical Units: Subjects			
Female	5263		
Male	13839		

Reporting group values	Safety set angina		
Number of subjects	1203		
Age categorical Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age continuous Units: years			
arithmetic mean			
standard deviation	\pm		
Gender categorical Units: Subjects			
Female			
Male			

End points

End points reporting groups

Reporting group title	Ivabradine
Reporting group description:	
Patients taking Ivabradine	
Reporting group title	Placebo
Reporting group description:	
Patients taking placebo	
Subject analysis set title	Randomised set
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
All included patients with a randomisation number allocated by the IRS.	
Subject analysis set title	Safety set
Subject analysis set type	Safety analysis
Subject analysis set description:	
All patients having received at least one dose of study drug.	
Subject analysis set title	Randomised set angina
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
All symptomatic angina patients of the RS having a CCS class \geq II at baseline (defined as CCS class \geq II at selection and inclusion).	
Subject analysis set title	Safety set angina
Subject analysis set type	Safety analysis
Subject analysis set description:	
All symptomatic angina patients of the SS having a CCS class \geq II at baseline (defined as CCS class \geq II at selection and inclusion).	

Primary: Primary composite endpoint

End point title	Primary composite endpoint
End point description:	
First event among cardiovascular death or non-fatal MI	
End point type	Primary
End point timeframe:	
All criteria are expressed as the time to first event, defined as the duration between the date of randomisation and the date of first occurrence of this event.	

End point values	Ivabradine	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9550	9552		
Units: number of events	654	611		

Statistical analyses

Statistical analysis title	Superiority of Ivabradine versus Placebo
Comparison groups	Ivabradine v Placebo
Number of subjects included in analysis	19102
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1969
Method	Regression, Cox
Parameter estimate	Cox proportional hazard
Point estimate	1.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.2
Variability estimate	Standard error of the mean
Dispersion value	0.06

Adverse events

Adverse events information

Timeframe for reporting adverse events:

On treatment

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.0
--------------------	------

Reporting groups

Reporting group title	Ivabradine
-----------------------	------------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	Ivabradine	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	3379 / 9539 (35.42%)	3263 / 9544 (34.19%)	
number of deaths (all causes)	363	356	
number of deaths resulting from adverse events	1	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute leukaemia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute myeloid leukaemia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma gastric			
subjects affected / exposed	6 / 9539 (0.06%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 2	
Adenocarcinoma of colon			

subjects affected / exposed	8 / 9539 (0.08%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma pancreas			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenolymphoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal adenoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenosquamous cell lung cancer			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Anal squamous cell carcinoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiofibroma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Astrocytoma, low grade			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
B precursor type acute leukaemia			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Basal cell carcinoma			
subjects affected / exposed	24 / 9539 (0.25%)	21 / 9544 (0.22%)	
occurrences causally related to treatment / all	0 / 25	0 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basosquamous carcinoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basosquamous carcinoma of skin			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign breast neoplasm			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of prostate			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of thyroid gland			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign pleural neoplasm			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign renal neoplasm			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct cancer			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	6 / 9539 (0.06%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer recurrent			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer stage I, with cancer in situ			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer stage II			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder papilloma			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			
subjects affected / exposed	5 / 9539 (0.05%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma recurrent			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma stage II			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma stage III			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bowen's disease			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain cancer metastatic			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain neoplasm			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Brain neoplasm malignant			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Brain stem glioma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Breast cancer			
subjects affected / exposed	0 / 9539 (0.00%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer metastatic			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Breast cancer recurrent			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer stage I			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer stage II			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial carcinoma			
subjects affected / exposed	5 / 9539 (0.05%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchioloalveolar carcinoma			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cancer pain			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carcinoid tumour of the stomach			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid body tumour			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Castleman's disease			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral hygroma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervix carcinoma			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cervix carcinoma stage III			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cholesteatoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic lymphocytic leukaemia			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic lymphocytic leukaemia stage 2			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell renal cell carcinoma			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell sarcoma of soft tissue			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon adenoma			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	6 / 9539 (0.06%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer metastatic			

subjects affected / exposed	6 / 9539 (0.06%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 3	0 / 1	
Colon cancer stage 0			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer metastatic			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma stage III			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma stage IV			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear neoplasm malignant			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial adenocarcinoma			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ependymoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extranodal marginal zone B-cell lymphoma (MALT type)			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder cancer			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder neoplasm			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric adenoma			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer			
subjects affected / exposed	3 / 9539 (0.03%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 2	
Gastric cancer stage IV			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal carcinoma			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stromal tumour			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal tract adenoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal cancer			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haemangioma of bone			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cancer			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 3	0 / 0	
Hepatic cancer metastatic			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Hepatocellular carcinoma			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hodgkin's disease			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal adenocarcinoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive ductal breast carcinoma			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large cell lung cancer			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large cell lung cancer metastatic			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Large cell lung cancer stage II			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine benign neoplasm			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer metastatic			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Laryngeal cancer recurrent			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Laryngeal squamous cell carcinoma			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Lentigo maligna			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip and/or oral cavity cancer			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 0	
Lip and/or oral cavity cancer stage IV			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			

subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma metastatic			
subjects affected / exposed	5 / 9539 (0.05%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 2	0 / 6	
Lung adenocarcinoma stage IV			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung cancer metastatic			
subjects affected / exposed	5 / 9539 (0.05%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 5	0 / 10	
deaths causally related to treatment / all	0 / 2	0 / 6	
Lung carcinoma cell type unspecified stage II			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lung carcinoma cell type unspecified stage IV			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lung neoplasm			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Lung neoplasm malignant			
subjects affected / exposed	7 / 9539 (0.07%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 7	0 / 12	
deaths causally related to treatment / all	0 / 3	0 / 5	
Lung squamous cell carcinoma metastatic			

subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Lung squamous cell carcinoma stage III			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphangiosis carcinomatosa			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Malignant ascites			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant glioma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant melanoma			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of ampulla of Vater			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of choroid			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of eyelid			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant oligodendroglioma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant pleural effusion			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesothelioma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to abdominal cavity			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastases to adrenals			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastases to bone			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Metastases to bone marrow			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastases to central nervous system			
subjects affected / exposed	3 / 9539 (0.03%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 0	
Metastases to eye			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to liver			
subjects affected / exposed	3 / 9539 (0.03%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 1	
Metastases to lung			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastases to lymph nodes			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastases to peritoneum			
subjects affected / exposed	0 / 9539 (0.00%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastases to the mediastinum			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to spine			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic bronchial carcinoma			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Metastatic carcinoma of the bladder			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastatic gastric cancer			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Metastatic malignant melanoma			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastatic neoplasm			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic renal cell carcinoma			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Metastatic pain			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic squamous cell carcinoma			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastatic uterine cancer			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Myelodysplastic syndrome			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelofibrosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myeloproliferative disorder			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngeal cancer			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Neoplasm			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm skin			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma metastatic			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine tumour			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodular melanoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-Hodgkin's lymphoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Non-small cell lung cancer			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Non-small cell lung cancer metastatic			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer stage IIIA			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma metastatic			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal carcinoma			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oesophageal squamous cell carcinoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oropharyngeal cancer			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian adenoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ovarian cancer metastatic			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian epithelial cancer metastatic			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian germ cell teratoma benign			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	2 / 9539 (0.02%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pancreatic carcinoma metastatic			
subjects affected / exposed	7 / 9539 (0.07%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 4	0 / 3	
Pancreatic neoplasm			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Papillary tumour of renal pelvis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parathyroid tumour benign			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penis carcinoma stage II			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pharyngeal cancer recurrent			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pineal parenchymal neoplasm malignant			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pituitary tumour benign			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pituitary tumour recurrent			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell leukaemia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Plasma cell myeloma			
subjects affected / exposed	2 / 9539 (0.02%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 2	
Pleural mesothelioma			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural neoplasm			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polycythaemia vera			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	38 / 9539 (0.40%)	18 / 9544 (0.19%)	
occurrences causally related to treatment / all	0 / 38	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer metastatic			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Prostate cancer recurrent			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage I			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage II			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage III			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage IV			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic adenoma			

subjects affected / exposed	4 / 9539 (0.04%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer			
subjects affected / exposed	5 / 9539 (0.05%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Rectal cancer metastatic			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Rectal cancer recurrent			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer stage 0			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer stage IV			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Rectosigmoid cancer			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal neoplasm			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer			
subjects affected / exposed	6 / 9539 (0.06%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal cancer metastatic			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer stage I			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal oncocytoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyosarcoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland adenoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland cancer			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer metastatic			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Small cell lung cancer metastatic			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Small intestine carcinoma			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal meningioma benign			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	3 / 9539 (0.03%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Squamous cell carcinoma of head and neck			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of lung			
subjects affected / exposed	4 / 9539 (0.04%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 2	0 / 2	
Squamous cell carcinoma of pharynx			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the cervix			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Squamous cell carcinoma of the hypopharynx			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Testicular cancer metastatic			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Throat cancer			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid cancer metastatic			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid neoplasm			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue neoplasm malignant stage unspecified			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Tonsil cancer			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Transitional cell carcinoma			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral cancer metastatic			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cancer			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	4 / 9539 (0.04%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm rupture			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Aortic arteriosclerosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dilatation			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dissection			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic occlusion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic thrombosis			
subjects affected / exposed	5 / 9539 (0.05%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial rupture			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial stenosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure fluctuation			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure inadequately controlled			
subjects affected / exposed	7 / 9539 (0.07%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	1 / 8	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	2 / 9539 (0.02%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	19 / 9539 (0.20%)	17 / 9544 (0.18%)	
occurrences causally related to treatment / all	0 / 19	1 / 17	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetic macroangiopathy			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic microangiopathy			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic vascular disorder			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Essential hypertension			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			
subjects affected / exposed	5 / 9539 (0.05%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral artery aneurysm			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral artery dissection			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral artery embolism			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral artery occlusion			

subjects affected / exposed	10 / 9539 (0.10%)	14 / 9544 (0.15%)	
occurrences causally related to treatment / all	0 / 11	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	204 / 9539 (2.14%)	144 / 9544 (1.51%)	
occurrences causally related to treatment / all	2 / 220	0 / 152	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	104 / 9539 (1.09%)	105 / 9544 (1.10%)	
occurrences causally related to treatment / all	1 / 117	0 / 119	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency			
subjects affected / exposed	13 / 9539 (0.14%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	1 / 15	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	25 / 9539 (0.26%)	36 / 9544 (0.38%)	
occurrences causally related to treatment / all	5 / 26	0 / 37	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	1 / 9539 (0.01%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Iliac artery occlusion			
subjects affected / exposed	1 / 9539 (0.01%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iliac artery rupture			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			
subjects affected / exposed	5 / 9539 (0.05%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jugular vein thrombosis			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Labile blood pressure			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Labile hypertension			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leriche syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoedema			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphostasis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant hypertension			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	12 / 9539 (0.13%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	2 / 12	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pallor			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	52 / 9539 (0.55%)	67 / 9544 (0.70%)	
occurrences causally related to treatment / all	0 / 58	0 / 70	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery aneurysm			
subjects affected / exposed	3 / 9539 (0.03%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery dissection			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	13 / 9539 (0.14%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 16	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	6 / 9539 (0.06%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	5 / 9539 (0.05%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 1	
Peripheral vascular disorder			
subjects affected / exposed	1 / 9539 (0.01%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phlebitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phlebitis superficial			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock haemorrhagic			
subjects affected / exposed	3 / 9539 (0.03%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 1	
Subclavian artery occlusion			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian artery stenosis			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian steal syndrome			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subgaleal haematoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systolic hypertension			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			
subjects affected / exposed	5 / 9539 (0.05%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose ulceration			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasculitis			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasculitis necrotising			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vena cava thrombosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous insufficiency			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Withdrawal hypertension			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Abdominal hernia repair			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol detoxification			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm repair			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic bypass			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve repair			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve replacement			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial bypass operation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial stent insertion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula operation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm surgery			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blepharoplasty			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bunion operation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac ablation			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac aneurysm repair			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac rehabilitation therapy			
subjects affected / exposed	23 / 9539 (0.24%)	19 / 9544 (0.20%)	
occurrences causally related to treatment / all	0 / 30	0 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid angioplasty			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery bypass			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stent insertion			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid endarterectomy			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract operation			
subjects affected / exposed	9 / 9539 (0.09%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 9	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chemotherapy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystectomy			
subjects affected / exposed	6 / 9539 (0.06%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholesteatoma removal			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circumcision			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary angioplasty			
subjects affected / exposed	1 / 9539 (0.01%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary arterial stent insertion			

subjects affected / exposed	5 / 9539 (0.05%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery bypass			
subjects affected / exposed	10 / 9539 (0.10%)	18 / 9544 (0.19%)	
occurrences causally related to treatment / all	0 / 10	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary revascularisation			
subjects affected / exposed	8 / 9539 (0.08%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus management			
subjects affected / exposed	4 / 9539 (0.04%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dupuytren's contracture operation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fasciectomy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral hernia repair			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Finger amputation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrectomy			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric banding			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric bypass			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma surgery			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip arthroplasty			
subjects affected / exposed	9 / 9539 (0.09%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 10	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hospitalisation			
subjects affected / exposed	8 / 9539 (0.08%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 13	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocele operation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileostomy closure			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implantable defibrillator insertion			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia repair			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infusion			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia repair			
subjects affected / exposed	3 / 9539 (0.03%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 3	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Internal fixation of fracture			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraocular lens extraction			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratoplasty			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee arthroplasty			
subjects affected / exposed	4 / 9539 (0.04%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 4	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee operation			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leg amputation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lens extraction			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device removal			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver operation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus removal			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metatarsal excision			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve repair			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal polypectomy			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity surgery			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal septal operation			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oophorectomy bilateral			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Percutaneous coronary intervention			
subjects affected / exposed	15 / 9539 (0.16%)	16 / 9544 (0.17%)	
occurrences causally related to treatment / all	0 / 15	0 / 16	
deaths causally related to treatment / all	0 / 1	0 / 0	
Peripheral artery angioplasty			
subjects affected / exposed	0 / 9539 (0.00%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery bypass			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stent insertion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Physiotherapy			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radical hysterectomy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiotherapy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rehabilitation therapy			
subjects affected / exposed	8 / 9539 (0.08%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 12	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Removal of internal fixation			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery ablation			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal stone removal			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal laser coagulation			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff repair			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shoulder arthroplasty			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus operation			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin neoplasm excision			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal operation			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suture insertion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroidectomy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toe amputation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transurethral prostatectomy			

subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia repair			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral dilation procedure			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary calculus removal			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine polypectomy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal prolapse repair			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Apparent death			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			
subjects affected / exposed	3 / 9539 (0.03%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 3	2 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac death			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Chest discomfort			
subjects affected / exposed	3 / 9539 (0.03%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	1 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	32 / 9539 (0.34%)	36 / 9544 (0.38%)	
occurrences causally related to treatment / all	0 / 35	0 / 50	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chills			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	10 / 9539 (0.10%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 10	0 / 7	
deaths causally related to treatment / all	0 / 10	0 / 7	
Device breakage			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device dislocation			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device extrusion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device failure			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device occlusion			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Discomfort			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drowning			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Drug interaction			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exercise tolerance decreased			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Face oedema			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			

subjects affected / exposed	7 / 9539 (0.07%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	2 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Feeling abnormal			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Feeling cold			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body reaction			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	1 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised oedema			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernia obstructive			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Irritability			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device complication			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multi-organ failure			
subjects affected / exposed	5 / 9539 (0.05%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 3	0 / 3	
Non-cardiac chest pain			
subjects affected / exposed	38 / 9539 (0.40%)	29 / 9544 (0.30%)	
occurrences causally related to treatment / all	0 / 43	1 / 31	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	9 / 9539 (0.09%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 9	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pacemaker generated arrhythmia			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Puncture site haemorrhage			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	5 / 9539 (0.05%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stent-graft endoleak			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden cardiac death			
subjects affected / exposed	43 / 9539 (0.45%)	46 / 9544 (0.48%)	
occurrences causally related to treatment / all	0 / 43	0 / 46	
deaths causally related to treatment / all	0 / 43	0 / 46	
Sudden death			
subjects affected / exposed	75 / 9539 (0.79%)	74 / 9544 (0.78%)	
occurrences causally related to treatment / all	0 / 75	0 / 74	
deaths causally related to treatment / all	0 / 75	0 / 74	
Systemic inflammatory response syndrome			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis in device			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Immune system disorders			
Allergy to arthropod sting			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amyloidosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic reaction			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic shock			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Drug hypersensitivity			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food allergy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			
Activities of daily living impaired			
subjects affected / exposed	11 / 9539 (0.12%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	11 / 11	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol use			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immobile			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired driving ability			
subjects affected / exposed	15 / 9539 (0.16%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	15 / 15	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Acquired hydrocele			
subjects affected / exposed	0 / 9539 (0.00%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acquired phimosis			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign prostatic hyperplasia			
subjects affected / exposed	23 / 9539 (0.24%)	28 / 9544 (0.29%)	
occurrences causally related to treatment / all	0 / 23	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	

Breast disorder			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystocele			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Female genital tract fistula			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Genital prolapse			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gynaecomastia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic adhesions			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatomegaly			

subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterovaginal prolapse			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal haemorrhage			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicocele			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval disorder			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acquired tracheo-oesophageal fistula			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute pulmonary oedema			
subjects affected / exposed	31 / 9539 (0.32%)	30 / 9544 (0.31%)	
occurrences causally related to treatment / all	0 / 33	0 / 32	
deaths causally related to treatment / all	0 / 4	0 / 4	
Acute respiratory distress syndrome			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute respiratory failure			
subjects affected / exposed	13 / 9539 (0.14%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	1 / 13	0 / 13	
deaths causally related to treatment / all	0 / 3	0 / 1	
Alveolitis allergic			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asphyxia			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Asthma			
subjects affected / exposed	21 / 9539 (0.22%)	16 / 9544 (0.17%)	
occurrences causally related to treatment / all	0 / 22	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspiration			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Asthmatic crisis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atelectasis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiectasis			

subjects affected / exposed	5 / 9539 (0.05%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis chronic			
subjects affected / exposed	5 / 9539 (0.05%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumopathy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	5 / 9539 (0.05%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 5	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Choking			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	64 / 9539 (0.67%)	52 / 9544 (0.54%)	
occurrences causally related to treatment / all	0 / 84	0 / 62	
deaths causally related to treatment / all	0 / 1	0 / 1	
Chronic respiratory failure			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cough			
subjects affected / exposed	7 / 9539 (0.07%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cyanosis central			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diaphragmatic paralysis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	23 / 9539 (0.24%)	23 / 9544 (0.24%)	
occurrences causally related to treatment / all	0 / 25	2 / 26	
deaths causally related to treatment / all	0 / 0	0 / 1	
Dyspnoea at rest			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	1 / 9539 (0.01%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	1 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysema			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	4 / 9539 (0.04%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Granulomatous pneumonitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			

subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	0 / 9539 (0.00%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydropneumothorax			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hydrothorax			
subjects affected / exposed	6 / 9539 (0.06%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	6 / 9539 (0.06%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Laryngeal stenosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung consolidation			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung cyst			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infiltration			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal polyps			
subjects affected / exposed	2 / 9539 (0.02%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal septum deviation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive airways disorder			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Organising pneumonia			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal oedema			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pickwickian syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	8 / 9539 (0.08%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural fibrosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural haemorrhage			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pleurisy			
subjects affected / exposed	2 / 9539 (0.02%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	7 / 9539 (0.07%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonitis			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			

subjects affected / exposed	2 / 9539 (0.02%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary arterial hypertension			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary artery thrombosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary congestion			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	15 / 9539 (0.16%)	24 / 9544 (0.25%)	
occurrences causally related to treatment / all	0 / 15	0 / 24	
deaths causally related to treatment / all	0 / 5	0 / 8	
Pulmonary fibrosis			
subjects affected / exposed	4 / 9539 (0.04%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary granuloma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	19 / 9539 (0.20%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 19	0 / 10	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pulmonary mass			

subjects affected / exposed	1 / 9539 (0.01%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary microemboli			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary oedema			
subjects affected / exposed	15 / 9539 (0.16%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 16	0 / 12	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary thrombosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Reflux laryngitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiration abnormal			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory acidosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory arrest			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory disorder			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	21 / 9539 (0.22%)	27 / 9544 (0.28%)	
occurrences causally related to treatment / all	0 / 21	0 / 28	
deaths causally related to treatment / all	0 / 5	0 / 6	
Sinus polyp			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep apnoea syndrome			
subjects affected / exposed	7 / 9539 (0.07%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Snoring			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Status asthmaticus			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachypnoea			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord polyp			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wheezing			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Acute psychosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aggression			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Agitated depression			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Agitation			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol abuse			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol withdrawal syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcoholism			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bipolar I disorder			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bipolar disorder			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Completed suicide			
subjects affected / exposed	0 / 9539 (0.00%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 4	
Confusional state			
subjects affected / exposed	7 / 9539 (0.07%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	1 / 7	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	8 / 9539 (0.08%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 9	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium tremens			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delusional disorder, unspecified type			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depressed mood			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	1 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	57 / 9539 (0.60%)	54 / 9544 (0.57%)	
occurrences causally related to treatment / all	0 / 59	0 / 54	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression suicidal			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depressive symptom			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disorientation			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysthymic disorder			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination, auditory			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination, visual			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucinations, mixed			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impulsive behaviour			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Insomnia			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional drug misuse			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mood disorder due to a general medical condition			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervousness			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obsessive thoughts			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Panic attack			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paranoia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Persecutory delusion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychomotor retardation			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychosomatic disease			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychotic disorder due to a general medical condition			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychotic disorder			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sleep disorder			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep terror			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Alcoholic liver disease			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stone			

subjects affected / exposed	4 / 9539 (0.04%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Biliary cirrhosis primary			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary tract disorder			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	2 / 9539 (0.02%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	9 / 9539 (0.09%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 10	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	19 / 9539 (0.20%)	17 / 9544 (0.18%)	
occurrences causally related to treatment / all	0 / 19	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis chronic			

subjects affected / exposed	7 / 9539 (0.07%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	12 / 9539 (0.13%)	20 / 9544 (0.21%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cholestasis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatitis			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cirrhosis alcoholic			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder perforation			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder polyp			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			

subjects affected / exposed	7 / 9539 (0.07%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic congestion			
subjects affected / exposed	1 / 9539 (0.01%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cyst			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic mass			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic steatosis			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis alcoholic			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis cholestatic			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatomegaly			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperbilirubinaemia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic hepatitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver disorder			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver injury			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portal vein thrombosis			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sphincter of Oddi dysfunction			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post cholecystectomy syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	11 / 9539 (0.12%)	11 / 9544 (0.12%)	
occurrences causally related to treatment / all	0 / 11	1 / 11	
deaths causally related to treatment / all	0 / 0	0 / 1	
Amylase increased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriogram carotid			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriogram coronary			
subjects affected / exposed	43 / 9539 (0.45%)	53 / 9544 (0.56%)	
occurrences causally related to treatment / all	0 / 45	0 / 58	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthroscopy			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			

subjects affected / exposed	12 / 9539 (0.13%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 12	1 / 10	
deaths causally related to treatment / all	0 / 0	0 / 1	
Biopsy prostate			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose decreased			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose increased			
subjects affected / exposed	2 / 9539 (0.02%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood iron decreased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood lactate dehydrogenase increased			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood parathyroid hormone decreased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium decreased			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium increased			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure decreased			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure increased			
subjects affected / exposed	24 / 9539 (0.25%)	13 / 9544 (0.14%)	
occurrences causally related to treatment / all	0 / 26	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure systolic decreased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure systolic increased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood triglycerides increased			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Body temperature increased			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
C-reactive protein increased			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac enzymes increased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbohydrate antigen 19-9 increased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac stress test abnormal			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiovascular evaluation			
subjects affected / exposed	78 / 9539 (0.82%)	84 / 9544 (0.88%)	
occurrences causally related to treatment / all	0 / 98	0 / 100	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheterisation cardiac			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystoscopy normal			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest X-ray abnormal			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ECG signs of myocardial ischaemia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram QT prolonged			
subjects affected / exposed	57 / 9539 (0.60%)	18 / 9544 (0.19%)	
occurrences causally related to treatment / all	42 / 60	6 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram ST segment depression			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram ST segment elevation			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram T wave inversion			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram ambulatory			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram change			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram repolarisation abnormality			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibrin D dimer increased			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal examination			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	2 / 9539 (0.02%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart rate decreased			
subjects affected / exposed	55 / 9539 (0.58%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	40 / 55	4 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			

subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio increased			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraocular pressure increased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigation			
subjects affected / exposed	7 / 9539 (0.07%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oxygen saturation decreased			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary arterial pressure increased			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Red blood cell sedimentation rate increased			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Romberg test positive			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep study			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcus test positive			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress echocardiogram abnormal			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid function test abnormal			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Treponema test positive			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			
subjects affected / exposed	5 / 9539 (0.05%)	11 / 9544 (0.12%)	
occurrences causally related to treatment / all	0 / 5	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cell count increased			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Abdominal injury			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wound dehiscence			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accident			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accident at home			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental overdose			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Agitation postoperative			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia postoperative			

subjects affected / exposed	2 / 9539 (0.02%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	6 / 9539 (0.06%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic injury			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial restenosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropod sting			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asbestosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back injury			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blindness traumatic			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone fissure			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain contusion			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Burns second degree			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbon monoxide poisoning			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac contusion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac procedure complication			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac valve replacement complication			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac valve rupture			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery restenosis			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest injury			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	1 / 9539 (0.01%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	6 / 9539 (0.06%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	9 / 9539 (0.09%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery restenosis			
subjects affected / exposed	9 / 9539 (0.09%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 9	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Corrosive gastritis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			

subjects affected / exposed	2 / 9539 (0.02%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crushing injury of trunk			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extradural haematoma			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye contusion			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye injury			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Face injury			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	1 / 9539 (0.01%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile nonhaemolytic transfusion reaction			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			

subjects affected / exposed	95 / 9539 (1.00%)	109 / 9544 (1.14%)	
occurrences causally related to treatment / all	4 / 96	2 / 109	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	13 / 9539 (0.14%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 13	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	15 / 9539 (0.16%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 15	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula fracture			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	5 / 9539 (0.05%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm fracture			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body in eye			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			

subjects affected / exposed	3 / 9539 (0.03%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	4 / 9539 (0.04%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	1 / 4	2 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heat stroke			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	6 / 9539 (0.06%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	4 / 9539 (0.04%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ilium fracture			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	0 / 9539 (0.00%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional overdose			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc injury			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal anastomosis complication			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaw fracture			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation postoperative			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	1 / 9539 (0.01%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney rupture			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laceration			

subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament sprain			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb crushing injury			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb traumatic amputation			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip injury			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			

subjects affected / exposed	4 / 9539 (0.04%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Meniscus injury			
subjects affected / exposed	2 / 9539 (0.02%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 1	
Muscle rupture			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck injury			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoradionecrosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic injury			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penetrating abdominal trauma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital haematoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery restenosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumoconiosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax traumatic			
subjects affected / exposed	2 / 9539 (0.02%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural contusion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural complication			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Post procedural fistula			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	3 / 9539 (0.03%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematuria			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural hypothyroidism			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	3 / 9539 (0.03%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Post procedural myocardial infarction			
subjects affected / exposed	14 / 9539 (0.15%)	13 / 9544 (0.14%)	
occurrences causally related to treatment / all	0 / 14	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 1	
Post procedural pulmonary embolism			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-thoracotomy pain syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-traumatic pain			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative thoracic procedure complication			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative ileus			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound complication			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural hypertension			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural hypotension			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pain			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural site reaction			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pubis fracture			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation oesophagitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	8 / 9539 (0.08%)	15 / 9544 (0.16%)	
occurrences causally related to treatment / all	0 / 8	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal haematoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	23 / 9539 (0.24%)	26 / 9544 (0.27%)	
occurrences causally related to treatment / all	0 / 23	0 / 26	
deaths causally related to treatment / all	0 / 2	0 / 1	
Rib fracture			
subjects affected / exposed	8 / 9539 (0.08%)	15 / 9544 (0.16%)	
occurrences causally related to treatment / all	0 / 8	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shunt thrombosis			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Silicosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fractured base			
subjects affected / exposed	2 / 9539 (0.02%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column injury			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	3 / 9539 (0.03%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	5 / 9539 (0.05%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic rupture			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stab wound			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sternal fracture			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous haematoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	8 / 9539 (0.08%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Suture related complication			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon injury			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	1 / 9539 (0.01%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	6 / 9539 (0.06%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue injury			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transfusion reaction			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haematoma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic intracranial haemorrhage			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Traumatic ulcer			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			

subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	3 / 9539 (0.03%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft complication			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft occlusion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft thrombosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasoplegia syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound complication			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound necrosis			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Adenomatous polyposis coli			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital umbilical hernia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Factor V Leiden mutation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic myopathy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyloric stenosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Accelerated idioventricular rhythm			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Acute coronary syndrome			
subjects affected / exposed	17 / 9539 (0.18%)	21 / 9544 (0.22%)	
occurrences causally related to treatment / all	1 / 18	0 / 24	
deaths causally related to treatment / all	0 / 4	0 / 1	
Acute left ventricular failure			
subjects affected / exposed	2 / 9539 (0.02%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 1	
Acute myocardial infarction			
subjects affected / exposed	200 / 9539 (2.10%)	208 / 9544 (2.18%)	
occurrences causally related to treatment / all	2 / 216	0 / 229	
deaths causally related to treatment / all	0 / 23	0 / 23	
Adams-Stokes syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	294 / 9539 (3.08%)	330 / 9544 (3.46%)	
occurrences causally related to treatment / all	3 / 314	2 / 361	
deaths causally related to treatment / all	0 / 1	0 / 0	
Angina unstable			
subjects affected / exposed	409 / 9539 (4.29%)	433 / 9544 (4.54%)	
occurrences causally related to treatment / all	4 / 479	0 / 524	
deaths causally related to treatment / all	0 / 2	0 / 0	
Aortic valve disease			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve disease mixed			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve incompetence			

subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve sclerosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	12 / 9539 (0.13%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 12	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia supraventricular			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis coronary artery			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriospasm coronary			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	49 / 9539 (0.51%)	41 / 9544 (0.43%)	
occurrences causally related to treatment / all	0 / 52	0 / 45	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			

subjects affected / exposed	336 / 9539 (3.52%)	232 / 9544 (2.43%)	
occurrences causally related to treatment / all	22 / 381	2 / 262	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial tachycardia			
subjects affected / exposed	4 / 9539 (0.04%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	17 / 9539 (0.18%)	13 / 9544 (0.14%)	
occurrences causally related to treatment / all	4 / 17	1 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block first degree			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	2 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			
subjects affected / exposed	22 / 9539 (0.23%)	13 / 9544 (0.14%)	
occurrences causally related to treatment / all	10 / 22	7 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular dissociation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	101 / 9539 (1.06%)	21 / 9544 (0.22%)	
occurrences causally related to treatment / all	91 / 102	15 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left			
subjects affected / exposed	7 / 9539 (0.07%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac aneurysm			
subjects affected / exposed	5 / 9539 (0.05%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	15 / 9539 (0.16%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 16	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiac asthma			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac failure			
subjects affected / exposed	357 / 9539 (3.74%)	346 / 9544 (3.63%)	
occurrences causally related to treatment / all	13 / 415	2 / 394	
deaths causally related to treatment / all	0 / 16	0 / 14	
Cardiac failure acute			
subjects affected / exposed	37 / 9539 (0.39%)	23 / 9544 (0.24%)	
occurrences causally related to treatment / all	0 / 45	0 / 26	
deaths causally related to treatment / all	0 / 7	0 / 9	
Cardiac failure congestive			
subjects affected / exposed	31 / 9539 (0.32%)	24 / 9544 (0.25%)	
occurrences causally related to treatment / all	0 / 33	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 2	
Cardiac failure chronic			

subjects affected / exposed	25 / 9539 (0.26%)	29 / 9544 (0.30%)	
occurrences causally related to treatment / all	1 / 28	0 / 36	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiac tamponade			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock			
subjects affected / exposed	30 / 9539 (0.31%)	22 / 9544 (0.23%)	
occurrences causally related to treatment / all	0 / 30	0 / 22	
deaths causally related to treatment / all	0 / 12	0 / 9	
Cardiomegaly			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiomyopathy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiovascular insufficiency			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
Congestive cardiomyopathy			

subjects affected / exposed	2 / 9539 (0.02%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cor pulmonale			
subjects affected / exposed	6 / 9539 (0.06%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 6	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coronary artery disease			
subjects affected / exposed	20 / 9539 (0.21%)	25 / 9544 (0.26%)	
occurrences causally related to treatment / all	0 / 21	0 / 25	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cor pulmonale chronic			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery dissection			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery insufficiency			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery occlusion			
subjects affected / exposed	14 / 9539 (0.15%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 14	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	18 / 9539 (0.19%)	26 / 9544 (0.27%)	
occurrences causally related to treatment / all	0 / 19	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery thrombosis			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dressler's syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis noninfective			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart valve incompetence			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive heart disease			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracardiac thrombus			
subjects affected / exposed	5 / 9539 (0.05%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cardiomyopathy			
subjects affected / exposed	3 / 9539 (0.03%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left atrial dilatation			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			

subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	9 / 9539 (0.09%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 10	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 1	
Left ventricular hypertrophy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Low cardiac output syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	16 / 9539 (0.17%)	14 / 9544 (0.15%)	
occurrences causally related to treatment / all	0 / 16	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve prolapse			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial depression			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial fibrosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Myocardial infarction			

subjects affected / exposed	98 / 9539 (1.03%)	83 / 9544 (0.87%)	
occurrences causally related to treatment / all	0 / 104	0 / 88	
deaths causally related to treatment / all	0 / 15	0 / 14	
Myocardial ischaemia			
subjects affected / exposed	23 / 9539 (0.24%)	27 / 9544 (0.28%)	
occurrences causally related to treatment / all	0 / 23	0 / 27	
deaths causally related to treatment / all	0 / 1	0 / 0	
Myocarditis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodal arrhythmia			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodal rhythm			
subjects affected / exposed	5 / 9539 (0.05%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	1 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	2 / 9539 (0.02%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	1 / 9539 (0.01%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	3 / 9539 (0.03%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postinfarction angina			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prinzmetal angina			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhythm idioventricular			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Right ventricular failure			
subjects affected / exposed	8 / 9539 (0.08%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 8	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Sick sinus syndrome			
subjects affected / exposed	9 / 9539 (0.09%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	4 / 9	4 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Silent myocardial infarction			
subjects affected / exposed	5 / 9539 (0.05%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinoatrial block			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus arrest			
subjects affected / exposed	9 / 9539 (0.09%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	8 / 9	4 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus arrhythmia			

subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus bradycardia			
subjects affected / exposed	48 / 9539 (0.50%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	42 / 49	4 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	6 / 9539 (0.06%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 6	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular extrasystoles			
subjects affected / exposed	8 / 9539 (0.08%)	15 / 9544 (0.16%)	
occurrences causally related to treatment / all	1 / 8	2 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	17 / 9539 (0.18%)	21 / 9544 (0.22%)	
occurrences causally related to treatment / all	1 / 18	0 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachyarrhythmia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Torsade de pointes			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tricuspid valve incompetence			
subjects affected / exposed	6 / 9539 (0.06%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trifascicular block			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ventricular extrasystoles			
subjects affected / exposed	32 / 9539 (0.34%)	21 / 9544 (0.22%)	
occurrences causally related to treatment / all	2 / 32	2 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular failure			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ventricular fibrillation			
subjects affected / exposed	20 / 9539 (0.21%)	20 / 9544 (0.21%)	
occurrences causally related to treatment / all	0 / 20	0 / 22	
deaths causally related to treatment / all	0 / 1	0 / 6	
Ventricular tachycardia			
subjects affected / exposed	35 / 9539 (0.37%)	21 / 9544 (0.22%)	
occurrences causally related to treatment / all	3 / 39	0 / 23	
deaths causally related to treatment / all	0 / 1	0 / 0	
Wolff-Parkinson-White syndrome			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Amnesia			
subjects affected / exposed	5 / 9539 (0.05%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	1 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Altered state of consciousness			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amyotrophic lateral sclerosis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anticholinergic syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aphasia			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	1 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ataxia			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autonomic neuropathy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain hypoxia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain injury			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain oedema			
subjects affected / exposed	1 / 9539 (0.01%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain stem infarction			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid aneurysm rupture			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid arteriosclerosis			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery aneurysm			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery disease			

subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery dissection			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery occlusion			
subjects affected / exposed	3 / 9539 (0.03%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	51 / 9539 (0.53%)	43 / 9544 (0.45%)	
occurrences causally related to treatment / all	0 / 57	0 / 45	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid sinus syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			
subjects affected / exposed	4 / 9539 (0.04%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar atrophy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cerebellar ischaemia			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral arteriosclerosis			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral artery stenosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral atrophy			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haematoma			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cerebral infarction			
subjects affected / exposed	15 / 9539 (0.16%)	13 / 9544 (0.14%)	
occurrences causally related to treatment / all	0 / 15	0 / 13	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cerebral ischaemia			

subjects affected / exposed	8 / 9539 (0.08%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 9	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral microangiopathy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	31 / 9539 (0.32%)	40 / 9544 (0.42%)	
occurrences causally related to treatment / all	0 / 32	0 / 44	
deaths causally related to treatment / all	0 / 5	0 / 5	
Cerebrovascular disorder			
subjects affected / exposed	5 / 9539 (0.05%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular insufficiency			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical cord compression			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical myelopathy			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicobrachial syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive disorder			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coma			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Convulsion			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	1 / 1	0 / 0	
Coordination abnormal			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cranial nerve disorder			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cranial nerve paralysis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cubital tunnel syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia			
subjects affected / exposed	4 / 9539 (0.04%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia Alzheimer's type			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia of the Alzheimer's type, with delusions			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Demyelinating polyneuropathy			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depressed level of consciousness			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic hyperglycaemic coma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	10 / 9539 (0.10%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 10	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	19 / 9539 (0.20%)	18 / 9544 (0.19%)	
occurrences causally related to treatment / all	3 / 19	3 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness postural			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drop attacks			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dystonic tremor			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalomyelitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	7 / 9539 (0.07%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Essential tremor			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extrapyramidal disorder			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial nerve disorder			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Grand mal convulsion			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paresis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Guillain-Barre syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic stroke			
subjects affected / exposed	5 / 9539 (0.05%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 6	0 / 12	
deaths causally related to treatment / all	0 / 4	0 / 5	
Headache			
subjects affected / exposed	5 / 9539 (0.05%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemianopia homonymous			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	6 / 9539 (0.06%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Horner's syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive encephalopathy			
subjects affected / exposed	2 / 9539 (0.02%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	3 / 9539 (0.03%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	1 / 3	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic coma			
subjects affected / exposed	2 / 9539 (0.02%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypoglycaemic unconsciousness			
subjects affected / exposed	4 / 9539 (0.04%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 4	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyporeflexia			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
IIIrd nerve paralysis			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intercostal neuralgia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial aneurysm			
subjects affected / exposed	4 / 9539 (0.04%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial hypotension			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial pressure increased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial venous sinus thrombosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cerebral infarction			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic neuropathy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	97 / 9539 (1.02%)	90 / 9544 (0.94%)	
occurrences causally related to treatment / all	1 / 100	0 / 95	
deaths causally related to treatment / all	0 / 13	0 / 6	
Lacunar infarction			
subjects affected / exposed	5 / 9539 (0.05%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lethargy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	32 / 9539 (0.34%)	22 / 9544 (0.23%)	
occurrences causally related to treatment / all	3 / 32	1 / 22	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	1 / 9539 (0.01%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Memory impairment			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monoplegia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Movement disorder			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple sclerosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myasthenia gravis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelitis transverse			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve compression			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve root compression			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve root lesion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuritis cranial			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurodegenerative disorder			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurological decompensation			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normal pressure hydrocephalus			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			

subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraplegia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinson's disease			
subjects affected / exposed	6 / 9539 (0.06%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinsonism			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Partial seizures			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral sensorimotor neuropathy			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy			
subjects affected / exposed	0 / 9539 (0.00%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Petit mal epilepsy			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poor quality sleep			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-injection delirium sedation syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-traumatic headache			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	15 / 9539 (0.16%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	4 / 15	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Posterior reversible encephalopathy syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychomotor hyperactivity			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyramidal tract syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radial nerve compression			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular pain			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular syndrome			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			
subjects affected / exposed	5 / 9539 (0.05%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Restless legs syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retrograde amnesia			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	2 / 9539 (0.02%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Senile dementia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Speech disorder			

subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somnolence			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal vascular disorder			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitic myelopathy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	5 / 9539 (0.05%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Subdural hygroma			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	91 / 9539 (0.95%)	89 / 9544 (0.93%)	
occurrences causally related to treatment / all	23 / 102	6 / 96	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thalamic infarction			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thalamus haemorrhage			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Thrombotic stroke			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonic convulsion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient global amnesia			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	56 / 9539 (0.59%)	50 / 9544 (0.52%)	
occurrences causally related to treatment / all	3 / 59	0 / 50	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulnar neurapraxia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulnar tunnel syndrome			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIIth nerve paralysis			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIth nerve disorder			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIth nerve paralysis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular dementia			
subjects affected / exposed	3 / 9539 (0.03%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular encephalopathy			
subjects affected / exposed	11 / 9539 (0.12%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 11	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral artery occlusion			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral artery stenosis			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			

subjects affected / exposed	15 / 9539 (0.16%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 15	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo CNS origin			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord paresis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wernicke-Korsakoff syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			
subjects affected / exposed	30 / 9539 (0.31%)	45 / 9544 (0.47%)	
occurrences causally related to treatment / all	0 / 30	0 / 45	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia folate deficiency			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia megaloblastic			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia vitamin B12 deficiency			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone marrow failure			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deficiency anaemia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disseminated intravascular coagulation			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Haemorrhagic diathesis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic anaemia			
subjects affected / exposed	14 / 9539 (0.15%)	15 / 9544 (0.16%)	
occurrences causally related to treatment / all	0 / 14	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic disorder			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heparin-induced thrombocytopenia			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypochromic anaemia			
subjects affected / exposed	8 / 9539 (0.08%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 8	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoprothrombinaemia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic thrombocytopenic purpura			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	7 / 9539 (0.07%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy mediastinal			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphopenia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microcytic anaemia			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrogenic anaemia			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normochromic normocytic anaemia			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Platelet dysfunction			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sideroblastic anaemia			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	15 / 9539 (0.16%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 17	1 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenic purpura			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	4 / 9539 (0.04%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deafness neurosensory			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deafness unilateral			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematotympanum			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hearing impaired			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoacusis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniere's disease			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurosensory hypoacusis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden hearing loss			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tinnitus			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tympanic membrane disorder			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	9 / 9539 (0.09%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	2 / 9	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular ataxia			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular disorder			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Age-related macular degeneration			
subjects affected / exposed	4 / 9539 (0.04%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amaurosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amaurosis fugax			
subjects affected / exposed	2 / 9539 (0.02%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angle closure glaucoma			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blindness			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	39 / 9539 (0.41%)	32 / 9544 (0.34%)	
occurrences causally related to treatment / all	0 / 43	0 / 32	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blindness unilateral			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract diabetic			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract nuclear			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract subcapsular			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Choroidal effusion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Choroidal neovascularisation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conjunctival haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dacryoadenitis acquired			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dacryostenosis acquired			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic glaucoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinal oedema			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinopathy			
subjects affected / exposed	9 / 9539 (0.09%)	18 / 9544 (0.19%)	
occurrences causally related to treatment / all	0 / 9	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diplopia			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	20 / 9539 (0.21%)	19 / 9544 (0.20%)	
occurrences causally related to treatment / all	0 / 20	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucomatous optic disc atrophy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratitis			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular degeneration			
subjects affected / exposed	7 / 9539 (0.07%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 8	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular fibrosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular oedema			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normal tension glaucoma			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular hypertension			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular icterus			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Open angle glaucoma			
subjects affected / exposed	3 / 9539 (0.03%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Optic atrophy			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmoplegia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Optic ischaemic neuropathy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papilloedema			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital oedema			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Photophobia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pterygium			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Photopsia			
subjects affected / exposed	28 / 9539 (0.29%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	29 / 31	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal aneurysm			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion			
subjects affected / exposed	2 / 9539 (0.02%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery thrombosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			
subjects affected / exposed	4 / 9539 (0.04%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal haemorrhage			
subjects affected / exposed	10 / 9539 (0.10%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 10	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal tear			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vascular thrombosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein occlusion			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein thrombosis			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinopathy haemorrhagic			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinopathy hypertensive			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinoschisis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vision blurred			
subjects affected / exposed	13 / 9539 (0.14%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	11 / 14	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual acuity reduced			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual impairment			
subjects affected / exposed	3 / 9539 (0.03%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	2 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous detachment			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous floaters			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	8 / 9539 (0.08%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 10	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal discomfort			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal distension			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia obstructive			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	6 / 9539 (0.06%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			

subjects affected / exposed	4 / 9539 (0.04%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal rigidity			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal strangulated hernia			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acquired oesophageal web			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute abdomen			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fissure			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal polyp			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal ulcer			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Barrett's oesophagus			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Colitis ulcerative			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonic pseudo-obstruction			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonic stenosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			

subjects affected / exposed	4 / 9539 (0.04%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dental alveolar anomaly			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gastroparesis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diaphragmatic hernia			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	10 / 9539 (0.10%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	1 / 10	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticular perforation			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis intestinal haemorrhagic			

subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			
subjects affected / exposed	3 / 9539 (0.03%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry mouth			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal haemorrhagic			
subjects affected / exposed	3 / 9539 (0.03%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal obstruction			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Duodenal polyp			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			

subjects affected / exposed	7 / 9539 (0.07%)	11 / 9544 (0.12%)	
occurrences causally related to treatment / all	0 / 7	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer perforation			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis haemorrhagic			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	4 / 9539 (0.04%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis haemorrhagic			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epigastric discomfort			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive duodenitis			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive oesophagitis			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecal incontinence			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flatulence			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Functional gastrointestinal disorder			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			

subjects affected / exposed	0 / 9539 (0.00%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastric mucosa erythema			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric polyps			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	8 / 9539 (0.08%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	10 / 9539 (0.10%)	15 / 9544 (0.16%)	
occurrences causally related to treatment / all	0 / 12	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer perforation			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastric varices			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric varices haemorrhage			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			

subjects affected / exposed	14 / 9539 (0.15%)	13 / 9544 (0.14%)	
occurrences causally related to treatment / all	0 / 14	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis atrophic			
subjects affected / exposed	5 / 9539 (0.05%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	10 / 9539 (0.10%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 10	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic			
subjects affected / exposed	5 / 9539 (0.05%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenal haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenitis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenitis haemorrhagic			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal angiodysplasia			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal angiodysplasia haemorrhagic			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal dysplasia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal erosion			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	13 / 9539 (0.14%)	11 / 9544 (0.12%)	
occurrences causally related to treatment / all	0 / 13	0 / 11	
deaths causally related to treatment / all	0 / 1	0 / 1	
Gastrooesophageal reflux disease			
subjects affected / exposed	12 / 9539 (0.13%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 12	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophagitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic erosive gastritis			

subjects affected / exposed	7 / 9539 (0.07%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	4 / 9539 (0.04%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernial eventration			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia			
subjects affected / exposed	7 / 9539 (0.07%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileal stenosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	3 / 9539 (0.03%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ileus paralytic			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	29 / 9539 (0.30%)	18 / 9544 (0.19%)	
occurrences causally related to treatment / all	0 / 31	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia strangulated			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia, obstructive			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal angina			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal fistula			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ischaemia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal mass			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	5 / 9539 (0.05%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal polyp			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal polyp haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Irritable bowel syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	11 / 9539 (0.12%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 11	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukoplakia oral			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip swelling			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	5 / 9539 (0.05%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mallory-Weiss syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mechanical ileus			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	6 / 9539 (0.06%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric artery thrombosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Mesenteric haemorrhage			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric occlusion			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mikulicz's disease			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	12 / 9539 (0.13%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 12	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedematous pancreatitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal achalasia			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal stenosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			

subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis haemorrhagic			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis ulcerative			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral submucosal fibrosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic pseudocyst			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	4 / 9539 (0.04%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	9 / 9539 (0.09%)	17 / 9544 (0.18%)	
occurrences causally related to treatment / all	1 / 9	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pancreatitis chronic			
subjects affected / exposed	11 / 9539 (0.12%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 11	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periproctitis			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis ulcerative			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	5 / 9539 (0.05%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal polyp			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal prolapse			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal ulcer haemorrhage			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reflux gastritis			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retching			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haemorrhage			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland calculus			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sigmoiditis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal perforation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic artery aneurysm			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			

subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Swollen tongue			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis mesenteric vessel			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tongue ulceration			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	4 / 9539 (0.04%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia, obstructive			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	8 / 9539 (0.08%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varices oesophageal			
subjects affected / exposed	4 / 9539 (0.04%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Volvulus			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	9 / 9539 (0.09%)	11 / 9544 (0.12%)	
occurrences causally related to treatment / all	1 / 9	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	4 / 9539 (0.04%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 4	3 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cold sweat			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decubitus ulcer			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis allergic			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis bullous			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatomyositis			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	4 / 9539 (0.04%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 4	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry gangrene			
subjects affected / exposed	2 / 9539 (0.02%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ecchymosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hidradenitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperhidrosis			
subjects affected / exposed	3 / 9539 (0.03%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 3	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keloid scar			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytoclastic vasculitis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lichen planus			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrobiosis lipoidica diabetorum			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic ulcer			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Panniculitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parapsoriasis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pruritus			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pemphigus			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pruritus allergic			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Purpura			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash generalised			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin lesion			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	2 / 9539 (0.02%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer haemorrhage			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Swelling face			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic skin eruption			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute prerenal failure			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anuria			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder dilatation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder diverticulum			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neck sclerosis			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder prolapse			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder perforation			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder stenosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder tamponade			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus bladder			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus ureteric			
subjects affected / exposed	7 / 9539 (0.07%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urethral			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			

subjects affected / exposed	10 / 9539 (0.10%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 10	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis glandularis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis haemorrhagic			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis noninfective			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic nephropathy			
subjects affected / exposed	11 / 9539 (0.12%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 12	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysuria			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerulonephritis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	6 / 9539 (0.06%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			

subjects affected / exposed	6 / 9539 (0.06%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydroureter			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive nephropathy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertonic bladder			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
IgA nephropathy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incontinence			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephroangiosclerosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	7 / 9539 (0.07%)	14 / 9544 (0.15%)	
occurrences causally related to treatment / all	0 / 7	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy toxic			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive uropathy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pollakiuria			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prerenal failure			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery occlusion			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	6 / 9539 (0.06%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery thrombosis			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	38 / 9539 (0.40%)	30 / 9544 (0.31%)	
occurrences causally related to treatment / all	1 / 39	0 / 30	
deaths causally related to treatment / all	0 / 0	0 / 3	
Renal failure acute			
subjects affected / exposed	29 / 9539 (0.30%)	35 / 9544 (0.37%)	
occurrences causally related to treatment / all	0 / 31	0 / 38	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal failure chronic			
subjects affected / exposed	34 / 9539 (0.36%)	17 / 9544 (0.18%)	
occurrences causally related to treatment / all	1 / 35	0 / 17	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal impairment			
subjects affected / exposed	13 / 9539 (0.14%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 14	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal infarct			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal ischaemia			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal tubular acidosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress urinary incontinence			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tubulointerstitial nephritis			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric obstruction			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric stenosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral disorder			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral obstruction			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			

subjects affected / exposed	3 / 9539 (0.03%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary bladder haemorrhage			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary bladder polyp			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	12 / 9539 (0.13%)	18 / 9544 (0.19%)	
occurrences causally related to treatment / all	0 / 14	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vesicoureteric reflux			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Autoimmune thyroiditis			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal insufficiency			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basedow's disease			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cushing's syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Empty sella syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Goitre			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthyroidism			
subjects affected / exposed	6 / 9539 (0.06%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothyroidism			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic nodular goitre			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Amyotrophy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankylosing spondylitis			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthralgia			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	7 / 9539 (0.07%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
CREST syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondromalacia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondropathy			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dupuytren's contracture			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exostosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exostosis of jaw			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fasciitis			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fistula			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty tophus			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin pain			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemarthrosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc compression			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorder			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc displacement			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	12 / 9539 (0.13%)	20 / 9544 (0.21%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kyphosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	9 / 9539 (0.09%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mobility decreased			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle haemorrhage			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle tightness			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	3 / 9539 (0.03%)	11 / 9544 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	3 / 9539 (0.03%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal stiffness			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myopathy			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myopathy toxic			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic arthropathy			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	46 / 9539 (0.48%)	43 / 9544 (0.45%)	
occurrences causally related to treatment / all	0 / 47	0 / 48	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondritis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondrosis			
subjects affected / exposed	1 / 9539 (0.01%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	5 / 9539 (0.05%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis postmenopausal			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporotic fracture			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patellofemoral pain syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periarthritis			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyalgia rheumatica			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudarthrosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriatic arthropathy			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			

subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	4 / 9539 (0.04%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scoliosis			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	3 / 9539 (0.03%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	18 / 9539 (0.19%)	16 / 9544 (0.17%)	
occurrences causally related to treatment / all	0 / 18	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondyloarthropathy			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sympathetic posterior cervical syndrome			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovitis			

subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic sclerosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tenosynovitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral foraminal stenosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal wall abscess			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess jaw			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute hepatitis C			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute sinusitis			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal candidiasis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendiceal abscess			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	16 / 9539 (0.17%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 18	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerotic gangrene			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous graft site infection			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			

subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial diarrhoea			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial prostatitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Biliary tract infection			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Borrelia infection			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain abscess			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiolitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	16 / 9539 (0.17%)	22 / 9544 (0.23%)	
occurrences causally related to treatment / all	0 / 16	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumonia			
subjects affected / exposed	29 / 9539 (0.30%)	24 / 9544 (0.25%)	
occurrences causally related to treatment / all	0 / 33	0 / 26	
deaths causally related to treatment / all	0 / 1	0 / 2	
Bronchitis bacterial			
subjects affected / exposed	4 / 9539 (0.04%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter gastroenteritis			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Candida pneumonia			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Candidiasis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbuncle			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	23 / 9539 (0.24%)	18 / 9544 (0.19%)	
occurrences causally related to treatment / all	0 / 23	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis gangrenous			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis suppurative			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis infective			
subjects affected / exposed	5 / 9539 (0.05%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatitis C			

subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic sinusitis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	4 / 9539 (0.04%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cystitis klebsiella			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue fever			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	1 / 9539 (0.01%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	5 / 9539 (0.05%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gangrene			

subjects affected / exposed	4 / 9539 (0.04%)	13 / 9544 (0.14%)	
occurrences causally related to treatment / all	0 / 4	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	5 / 9539 (0.05%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear infection			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Echinococciasis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysematous cholecystitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Empyema			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis bacterial			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Endocarditis enterococcal			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis staphylococcal			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Enterobacter sepsis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal sepsis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis bacterial			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis infectious			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiglottitis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			

subjects affected / exposed	20 / 9539 (0.21%)	15 / 9544 (0.16%)	
occurrences causally related to treatment / all	0 / 20	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia infection			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	2 / 9539 (0.02%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Folliculitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder empyema			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	7 / 9539 (0.07%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastroenteritis			
subjects affected / exposed	16 / 9539 (0.17%)	16 / 9544 (0.17%)	
occurrences causally related to treatment / all	0 / 16	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis bacterial			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis clostridial			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis salmonella			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis shigella			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal bacterial infection			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal viral infection			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemophilus infection			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Helicobacter gastritis			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Helicobacter infection			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis A			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis B			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis C			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	1 / 9539 (0.01%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster infection neurological			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster ophthalmic			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster oticus			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected cyst			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected dermal cyst			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious pleural effusion			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of bronchiectasis			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	5 / 9539 (0.05%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective myositis			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injection site abscess			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral discitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint abscess			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratitis herpetic			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis bacterial			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis fungal			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Legionella infection			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lobar pneumonia			
subjects affected / exposed	6 / 9539 (0.06%)	13 / 9544 (0.14%)	
occurrences causally related to treatment / all	0 / 6	0 / 13	
deaths causally related to treatment / all	0 / 1	0 / 0	
Localised infection			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	5 / 9539 (0.05%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 5	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection bacterial			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung abscess			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			

subjects affected / exposed	11 / 9539 (0.12%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 11	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lyme disease			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphangitis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaria			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastoiditis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinal abscess			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis tuberculous			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis viral			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle abscess			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising fasciitis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
subjects affected / exposed	2 / 9539 (0.02%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	2 / 9539 (0.02%)	11 / 9544 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis bacterial			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis chronic			

subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media acute			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media chronic			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic abscess			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perihepatic abscess			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perineal abscess			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal abscess			

subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	9 / 9539 (0.09%)	9 / 9544 (0.09%)	
occurrences causally related to treatment / all	0 / 9	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 2	
Peritonitis bacterial			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillar abscess			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pertussis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumococcal sepsis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	122 / 9539 (1.28%)	102 / 9544 (1.07%)	
occurrences causally related to treatment / all	0 / 129	0 / 112	
deaths causally related to treatment / all	0 / 6	0 / 3	
Pneumonia bacterial			

subjects affected / exposed	7 / 9539 (0.07%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonia escherichia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia haemophilus			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia klebsiella			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia moraxella			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia mycoplasmal			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pseudomonas aeruginosa			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia streptococcal			

subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural cellulitis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Post procedural sepsis			
subjects affected / exposed	1 / 9539 (0.01%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative abscess			
subjects affected / exposed	0 / 9539 (0.00%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	6 / 9539 (0.06%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 6	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomembranous colitis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomonal bacteraemia			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary sepsis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculoma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculosis			
subjects affected / exposed	4 / 9539 (0.04%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Puncture site abscess			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Puncture site infection			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	3 / 9539 (0.03%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	5 / 9539 (0.05%)	8 / 9544 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis chronic			

subjects affected / exposed	7 / 9539 (0.07%)	6 / 9544 (0.06%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyoderma			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyonephrosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal tuberculosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory moniliasis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	5 / 9539 (0.05%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 5	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection bacterial			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection viral			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonellosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	11 / 9539 (0.12%)	11 / 9544 (0.12%)	
occurrences causally related to treatment / all	0 / 11	0 / 11	
deaths causally related to treatment / all	0 / 5	0 / 3	
Scrotal abscess			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic arthritis staphylococcal			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	9 / 9539 (0.09%)	13 / 9544 (0.14%)	
occurrences causally related to treatment / all	0 / 9	0 / 13	
deaths causally related to treatment / all	0 / 6	0 / 5	
Sinusitis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestine gangrene			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sputum purulent			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	2 / 9539 (0.02%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal osteomyelitis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	2 / 9539 (0.02%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Streptococcal sepsis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	4 / 9539 (0.04%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic candida			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis bacterial			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth infection			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic shock syndrome			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis gastrointestinal			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculous pleurisy			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tubo-ovarian abscess			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Typhoid fever			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			

subjects affected / exposed	6 / 9539 (0.06%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	26 / 9539 (0.27%)	17 / 9544 (0.18%)	
occurrences causally related to treatment / all	0 / 26	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	7 / 9539 (0.07%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection enterococcal			
subjects affected / exposed	2 / 9539 (0.02%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	4 / 9539 (0.04%)	13 / 9544 (0.14%)	
occurrences causally related to treatment / all	0 / 4	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 1	
Viral infection			
subjects affected / exposed	3 / 9539 (0.03%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral pericarditis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection bacterial			

subjects affected / exposed	3 / 9539 (0.03%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection pseudomonas			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cachexia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	1 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	19 / 9539 (0.20%)	19 / 9544 (0.20%)	
occurrences causally related to treatment / all	0 / 20	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	59 / 9539 (0.62%)	82 / 9544 (0.86%)	
occurrences causally related to treatment / all	0 / 65	0 / 87	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetes mellitus inadequate control			
subjects affected / exposed	34 / 9539 (0.36%)	50 / 9544 (0.52%)	
occurrences causally related to treatment / all	0 / 36	0 / 53	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic complication			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid retention			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	4 / 9539 (0.04%)	3 / 9544 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercholesterolaemia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	10 / 9539 (0.10%)	4 / 9544 (0.04%)	
occurrences causally related to treatment / all	0 / 11	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	13 / 9539 (0.14%)	10 / 9544 (0.10%)	
occurrences causally related to treatment / all	0 / 14	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertriglyceridaemia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			

subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	19 / 9539 (0.20%)	12 / 9544 (0.13%)	
occurrences causally related to treatment / all	0 / 20	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	4 / 9539 (0.04%)	5 / 9544 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	1 / 9539 (0.01%)	7 / 9544 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoproteinaemia			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Insulin-requiring type 2 diabetes mellitus			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketoacidosis			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lactic acidosis			

subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			
subjects affected / exposed	1 / 9539 (0.01%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic alkalosis			
subjects affected / exposed	0 / 9539 (0.00%)	2 / 9544 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			
subjects affected / exposed	0 / 9539 (0.00%)	1 / 9544 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 1 diabetes mellitus			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	25 / 9539 (0.26%)	47 / 9544 (0.49%)	
occurrences causally related to treatment / all	0 / 26	0 / 52	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 3 diabetes mellitus			
subjects affected / exposed	1 / 9539 (0.01%)	0 / 9544 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Ivabradine	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6920 / 9539 (72.54%)	6321 / 9544 (66.23%)	
Vascular disorders			
Hypertensive crisis			
subjects affected / exposed	129 / 9539 (1.35%)	140 / 9544 (1.47%)	
occurrences (all)	147	160	
Hypertension			
subjects affected / exposed	1129 / 9539 (11.84%)	923 / 9544 (9.67%)	
occurrences (all)	1322	1070	
Hypotension			
subjects affected / exposed	178 / 9539 (1.87%)	190 / 9544 (1.99%)	
occurrences (all)	187	198	
Peripheral arterial occlusive disease			
subjects affected / exposed	122 / 9539 (1.28%)	128 / 9544 (1.34%)	
occurrences (all)	131	135	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	108 / 9539 (1.13%)	132 / 9544 (1.38%)	
occurrences (all)	121	158	
Non-cardiac chest pain			
subjects affected / exposed	119 / 9539 (1.25%)	114 / 9544 (1.19%)	
occurrences (all)	131	123	
Fatigue			
subjects affected / exposed	126 / 9539 (1.32%)	110 / 9544 (1.15%)	
occurrences (all)	131	116	
Oedema peripheral			
subjects affected / exposed	214 / 9539 (2.24%)	170 / 9544 (1.78%)	
occurrences (all)	234	178	
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	121 / 9539 (1.27%)	132 / 9544 (1.38%)	
occurrences (all)	121	132	

Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	168 / 9539 (1.76%)	152 / 9544 (1.59%)	
occurrences (all)	211	198	
Cough			
subjects affected / exposed	154 / 9539 (1.61%)	138 / 9544 (1.45%)	
occurrences (all)	165	146	
Dyspnoea			
subjects affected / exposed	136 / 9539 (1.43%)	114 / 9544 (1.19%)	
occurrences (all)	144	121	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	100 / 9539 (1.05%)	99 / 9544 (1.04%)	
occurrences (all)	102	102	
Investigations			
Blood pressure increased			
subjects affected / exposed	118 / 9539 (1.24%)	117 / 9544 (1.23%)	
occurrences (all)	145	145	
Blood creatinine increased			
subjects affected / exposed	114 / 9539 (1.20%)	88 / 9544 (0.92%)	
occurrences (all)	118	89	
C-reactive protein increased			
subjects affected / exposed	155 / 9539 (1.62%)	140 / 9544 (1.47%)	
occurrences (all)	159	143	
Electrocardiogram QT prolonged			
subjects affected / exposed	161 / 9539 (1.69%)	58 / 9544 (0.61%)	
occurrences (all)	178	62	
Heart rate decreased			
subjects affected / exposed	1032 / 9539 (10.82%)	112 / 9544 (1.17%)	
occurrences (all)	1173	123	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	259 / 9539 (2.72%)	287 / 9544 (3.01%)	
occurrences (all)	284	313	
Cardiac disorders			

Acute myocardial infarction subjects affected / exposed occurrences (all)	200 / 9539 (2.10%) 216	208 / 9544 (2.18%) 229
Angina pectoris subjects affected / exposed occurrences (all)	611 / 9539 (6.41%) 684	692 / 9544 (7.25%) 774
Angina unstable subjects affected / exposed occurrences (all)	412 / 9539 (4.32%) 482	436 / 9544 (4.57%) 527
Atrioventricular block first degree subjects affected / exposed occurrences (all)	251 / 9539 (2.63%) 269	204 / 9544 (2.14%) 222
Atrial fibrillation subjects affected / exposed occurrences (all)	438 / 9539 (4.59%) 538	316 / 9544 (3.31%) 370
Cardiac failure subjects affected / exposed occurrences (all)	469 / 9539 (4.92%) 546	464 / 9544 (4.86%) 531
Bradycardia subjects affected / exposed occurrences (all)	569 / 9539 (5.96%) 613	77 / 9544 (0.81%) 84
Myocardial infarction subjects affected / exposed occurrences (all)	98 / 9539 (1.03%) 104	83 / 9544 (0.87%) 88
Sinus bradycardia subjects affected / exposed occurrences (all)	189 / 9539 (1.98%) 199	22 / 9544 (0.23%) 24
Sinus tachycardia subjects affected / exposed occurrences (all)	46 / 9539 (0.48%) 46	170 / 9544 (1.78%) 193
Supraventricular extrasystoles subjects affected / exposed occurrences (all)	184 / 9539 (1.93%) 194	143 / 9544 (1.50%) 144
Ventricular extrasystoles subjects affected / exposed occurrences (all)	335 / 9539 (3.51%) 363	264 / 9544 (2.77%) 288

Nervous system disorders	Dizziness			
	subjects affected / exposed	291 / 9539 (3.05%)	217 / 9544 (2.27%)	
	occurrences (all)	311	235	
	Headache			
	subjects affected / exposed	170 / 9539 (1.78%)	146 / 9544 (1.53%)	
	occurrences (all)	195	162	
Ischaemic stroke	subjects affected / exposed	97 / 9539 (1.02%)	90 / 9544 (0.94%)	
	occurrences (all)	100	95	
Blood and lymphatic system disorders				
Anaemia	subjects affected / exposed	214 / 9539 (2.24%)	240 / 9544 (2.51%)	
	occurrences (all)	221	249	
Eye disorders				
Cataract	subjects affected / exposed	157 / 9539 (1.65%)	189 / 9544 (1.98%)	
	occurrences (all)	175	203	
Photopsia	subjects affected / exposed	509 / 9539 (5.34%)	51 / 9544 (0.53%)	
	occurrences (all)	567	52	
Vision blurred	subjects affected / exposed	115 / 9539 (1.21%)	36 / 9544 (0.38%)	
	occurrences (all)	119	36	
Gastrointestinal disorders				
Constipation	subjects affected / exposed	99 / 9539 (1.04%)	102 / 9544 (1.07%)	
	occurrences (all)	106	107	
Diarrhoea	subjects affected / exposed	125 / 9539 (1.31%)	121 / 9544 (1.27%)	
	occurrences (all)	131	129	
Gastritis	subjects affected / exposed	108 / 9539 (1.13%)	124 / 9544 (1.30%)	
	occurrences (all)	111	127	
Nausea	subjects affected / exposed	96 / 9539 (1.01%)	83 / 9544 (0.87%)	
	occurrences (all)	102	87	

Renal and urinary disorders			
Renal failure			
subjects affected / exposed	112 / 9539 (1.17%)	89 / 9544 (0.93%)	
occurrences (all)	118	90	
Renal failure chronic			
subjects affected / exposed	105 / 9539 (1.10%)	82 / 9544 (0.86%)	
occurrences (all)	109	82	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	102 / 9539 (1.07%)	115 / 9544 (1.20%)	
occurrences (all)	107	121	
Arthralgia			
subjects affected / exposed	71 / 9539 (0.74%)	98 / 9544 (1.03%)	
occurrences (all)	75	102	
Osteoarthritis			
subjects affected / exposed	148 / 9539 (1.55%)	192 / 9544 (2.01%)	
occurrences (all)	163	209	
Spinal osteoarthritis			
subjects affected / exposed	125 / 9539 (1.31%)	134 / 9544 (1.40%)	
occurrences (all)	131	143	
Infections and infestations			
Bronchitis			
subjects affected / exposed	228 / 9539 (2.39%)	201 / 9544 (2.11%)	
occurrences (all)	257	226	
Influenza			
subjects affected / exposed	116 / 9539 (1.22%)	169 / 9544 (1.77%)	
occurrences (all)	126	177	
Pneumonia			
subjects affected / exposed	170 / 9539 (1.78%)	146 / 9544 (1.53%)	
occurrences (all)	183	161	
Nasopharyngitis			
subjects affected / exposed	172 / 9539 (1.80%)	172 / 9544 (1.80%)	
occurrences (all)	195	198	
Upper respiratory tract infection			
subjects affected / exposed	172 / 9539 (1.80%)	179 / 9544 (1.88%)	
occurrences (all)	200	219	

Urinary tract infection subjects affected / exposed occurrences (all)	129 / 9539 (1.35%) 137	116 / 9544 (1.22%) 136	
Metabolism and nutrition disorders			
Diabetes mellitus subjects affected / exposed occurrences (all)	241 / 9539 (2.53%) 264	320 / 9544 (3.35%) 347	
Diabetes mellitus inadequate control subjects affected / exposed occurrences (all)	109 / 9539 (1.14%) 115	132 / 9544 (1.38%) 141	
Hyperglycaemia subjects affected / exposed occurrences (all)	109 / 9539 (1.14%) 113	103 / 9544 (1.08%) 108	
Hypercholesterolaemia subjects affected / exposed occurrences (all)	155 / 9539 (1.62%) 162	175 / 9544 (1.83%) 184	
Hyperkalaemia subjects affected / exposed occurrences (all)	152 / 9539 (1.59%) 159	121 / 9544 (1.27%) 131	
Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	161 / 9539 (1.69%) 167	217 / 9544 (2.27%) 231	
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	150 / 9539 (1.57%) 154	159 / 9544 (1.67%) 162	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 June 2010	<p>Amendment No. 1 was applicable in all countries. The aims were:</p> <ul style="list-style-type: none">- To update the list of secondary efficacy endpoints: a new endpoint "coronary death" (a sub-category of cardiovascular deaths) was added, based on the BEAUTIFUL data, where the benefits of ivabradine had been observed mainly on coronary events;- To clarify the criteria for the documentation of the coronary artery disease (selection criteria). The e-CRF was modified to include more extensive details;- To update the definition of an excessive intake of the study drug and the rules for immediate notification to the sponsor;- To update administrative data (including the list of countries, the names and/or contact details of non-sponsor and sponsor parties), and to update the list of ancillary studies (Biomarkers of coronary artery disease ancillary study was added in selected centres). <p>The amendment did not require any changes to the patient information sheet or informed consent form.</p>
14 June 2011	<p>Amendment No. 2, was applicable in all countries. The aims were:</p> <ul style="list-style-type: none">- To increase the number of patients to be randomised (16 850 instead of 11 330 initially planned) and the extension of the estimated recruitment duration to 30 months (instead of 24 months). These changes were made on the basis of a revised annual incidence in blind for the primary composite endpoint of 2.5% in the overall population (corresponding to 2.7% in the placebo group), with unchanged power (90%), type I error (5%), and relative risk reduction (18%). The planned follow-up duration for the first included patients was extended from 42 months to 48 months.- To update the administrative data (including the list of countries, the names and / or contact details of non-sponsor and sponsor parties).- To clarify the types of source documents needed for the documentation of the CAD in the case of previous coronary revascularisation or presence of significant (> 50%) coronary artery stenosis.- To clarify that patient should receive stable doses of conventional CV medications during the run-in period. <p>This amendment required an amendment to the patient information and consent form. The amended form was to be signed by all patients as soon as the amendment became applicable in their centre: new patients were to sign the complete form, while patients already recruited in the study before the amendment were to sign the short form during their next visit after the amendment implementation.</p>
07 September 2012	<p>Amendment No. 4, was applicable in all countries. The aims were:</p> <ul style="list-style-type: none">- To update information on concomitant treatments to be used with precaution during the study (potassium-depleting diuretics).- To update the list of adverse events for which specific information was requested and already collected (bradycardia, eye disorders, rhythm and conduction disorders, blood pressure increases and QT prolongation).- Additional clarifications and corrections, including definitions of the intensity of adverse events (mild, moderate, and severe).- To update administrative data (Belarus and Saudi Arabia were removed from the list of participating countries). <p>This amendment required an amendment to the patient information and consent form.</p>

30 May 2013	Amendment No. 5 and amendment No. 6 were applicable in all countries where it was permitted to retrieve, for patients who withdrew their study consent, their vital status (amendment No. 5) and the dates of hospitalisations for CV events (amendment No. 6). The aims of these amendments were to minimise the number of patients with missing follow-up information of vital status and hospitalisations for cardiovascular events at the end of the study, while respecting the local regulations. The patients concerned by this procedure were those who withdrew consent from study after the randomisation/inclusion visit and before the start date of the termination visits (scheduled from 1 September to 31 December 2013). In the cases where there was information that a PSE occurred, no PSE file was prepared and the event was not adjudicated by the EVC. Depending on local regulations, these two amendments may or may not have required an amendment to the patient information and consent form.
-------------	--

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The section NSAE presented EAEs on treatment and included SEAEs. The causality and seriousness of reported SAE can be ultimately upgraded by the sponsor. The sponsor took these decisions to be compliant with the existing ICH E3 Clinical Study Report.
--

Notes: